fluphenazine has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barmada, SJ | 1 |
| Serio, A | 1 |
| Arjun, A | 1 |
| Bilican, B | 1 |
| Daub, A | 1 |
| Ando, DM | 1 |
| Tsvetkov, A | 1 |
| Pleiss, M | 1 |
| Li, X | 1 |
| Peisach, D | 1 |
| Shaw, C | 1 |
| Chandran, S | 1 |
| Finkbeiner, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rapamycin (Sirolimus) Treatment for Amyotrophic Lateral Sclerosis[NCT03359538] | Phase 2 | 63 participants (Actual) | Interventional | 2017-09-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for fluphenazine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models.
Topics: Amino Acid Sequence; Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Autophagy; Cell Survival; C | 2014 |